StreetInsider.com News Articles

Kala Bio signs LOI to acquire telehealth platform for ~$15M

Tue, 29 Sep 2026 07:32:15 -0400

Kala Bio, Inc. (NASDAQ: KALA) signed a non-binding letter of intent on September 24, 2026, to acquire a privately held management services organization supporting a telehealth platform serving clients in all 50 U.S. states, according to a company statement.

The proposed acquisition is valued at approximately $15 million, payable in a combination of cash and KALA stock. The cash portion is expected to be funded from existing balance sheet resources. The final allocation between cash and stock will be determined during due diligence.

The target, founded in 2023, is LegitScript-certified and NABP-accredited. It has served more than 90,000 clients since inception and

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Tue, 29 Sep 2026 07:30:00 -0400

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness

Key Highlights

Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive
Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources
Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception
45-day

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception

Tue, 29 Sep 2026 07:30:00 -0400

Key Highlights

Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive
Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources
Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception
45-day

Form DEF 14A KALA BIO, Inc. For: Nov 03

Thu, 24 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260924/27102289.html

Kala Bio and Virotek sign non-binding LOI to expand genetic testing

Thu, 24 Sep 2026 07:30:53 -0400

Kala Bio, Inc. (Nasdaq: KALA) and Virotek Inc. announced they have signed a non-binding letter of intent with an unnamed U.S. DNA testing platform that would resell a selected suite of Virotek's genomic testing products, according to a press release dated Sept. 24, 2026.

The proposed arrangement would extend the companies' existing collaboration beyond ophthalmology into broader genomic testing applications. Commercial and economic terms are still being finalized, and the companies said they expect to name the reselling parties in the coming weeks, assuming negotiations are completed.

The LOI follows an exclusive U.S. distribution and reseller agreement between Kala and Virotek announced

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Thu, 24 Sep 2026 07:30:00 -0400

ARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have signed a non-binding letter of intent (the "LOI") with a U.S. DNA testing platform under which the platform would resell Virotek's selected suite of genomic testing products. The mechanics of the commercial and economic terms are being finalized. Assuming negotiations are completed, the companies expect to name the reselling parties in the coming weeks.

The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3,

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Thu, 24 Sep 2026 07:30:00 -0400

The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3,

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Thu, 24 Sep 2026 07:30:00 -0400

Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Thu, 24 Sep 2026 07:30:00 -0400

Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel

Kala Bio adds healthcare operator Yenvy Truong to advisory team

Thu, 17 Sep 2026 07:31:11 -0400

Kala Bio, Inc. (Nasdaq: KALA) announced that Yenvy Truong, founder of The LSM Group, has joined the company's advisory team, according to a press release dated Sept. 17, 2026.

Truong will support management as Kala Bio grows its existing business and evaluates expansion opportunities, including potential acquisitions. She serves as an advisor and is neither an officer nor an employee of the company.

Truong has approximately two decades of experience in healthcare operations, including building and operating diagnostic laboratories. She has founded, scaled, and advised healthcare and life sciences companies across genomics, longevity, remote patient monitoring, digital musculoskeletal care, and metabolic medicine,

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Thu, 17 Sep 2026 07:30:00 -0400

Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq: KALA) ("KALA" or the "Company") today announced that Yenvy Truong, founder of The LSM Group, has joined the Company's advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions.

Ms. Truong has spent roughly two decades in healthcare operations, including building and operating diagnostic laboratories. She has founded, scaled, and advised healthcare and life sciences companies across

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Thu, 17 Sep 2026 07:30:00 -0400

Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions

Form PRE 14A KALA BIO, Inc. For: Sep 11

Fri, 11 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260911/27053523.html

Form 8-K KALA BIO, Inc. For: Sep 03

Thu, 10 Sep 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260910/27049481.html

Kala Bio signs exclusive U.S. deal to distribute Virotek eye genetic tests

Thu, 03 Sep 2026 08:33:02 -0400

Kala Bio, Inc. (Nasdaq: KALA) and Virotek Inc. have finalized an exclusive distribution and reseller agreement under which Kala will serve as the sole U.S. distributor of Virotek's ophthalmology genomic testing and screening program, according to a press release from the companies.

The agreement, which took effect September 4, 2026, grants Kala the right to market, promote, distribute, and resell Virotek's ophthalmology genetic testing program across the United States for an initial one-year term. Continued exclusivity depends on Kala meeting agreed commercial milestones. The agreement follows a non-binding letter of intent announced September 1, 2026.

Under the terms, Virotek retains responsibility for

Kala Bio signs exclusive U.S. deal to distribute Virotek eye genetic tests

Thu, 03 Sep 2026 08:33:02 -0400

Under the terms, Virotek retains responsibility for

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Thu, 03 Sep 2026 08:30:00 -0400

Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program

ARLINGTON, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have finalized a definitive exclusive distribution and reseller agreement (the "Agreement") and related quality, brand, and data protection agreements. Under the Agreement, Kala will be the exclusive distributor and reseller in the United States for an initial one-year term, with continued exclusivity contingent on Kala achieving agreed commercial milestones for Virotek's ophthalmology genetic testing and screening program. The Agreement follows the

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Thu, 03 Sep 2026 08:30:00 -0400

Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Tue, 01 Sep 2026 07:45:00 -0400

ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.

Under the framework outlined in the LOI, Kala would market, promote, and distribute Virotek's ophthalmology genetic testing and screening program to eye

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Tue, 01 Sep 2026 07:45:00 -0400

Under the framework outlined in the LOI, Kala would market, promote, and distribute Virotek's ophthalmology genetic testing and screening program to eye

Form 8-K KALA BIO, Inc. For: Aug 27

Fri, 28 Aug 2026 06:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26992863.html

Form 8-K KALA BIO, Inc. For: Aug 27

Fri, 28 Aug 2026 06:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26992863.html

Form 10-Q KALA BIO, Inc. For: Jun 30

Wed, 19 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260819/26950295.html

Form 10-Q KALA BIO, Inc. For: Jun 30

Wed, 19 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260819/26950295.html

Form NT 10-Q KALA BIO, Inc. For: Jun 30

Fri, 14 Aug 2026 10:14:00 -0400

si-local-file:///var/storage/secattach/20260814/26926230.html